ARTICLE | Company News
ASCO recommends MammaPrint to inform chemo use
July 13, 2017 11:46 PM UTC
In an update to its clinical practice guidelines for women with early breast cancer in the adjuvant setting, the American Society of Clinical Oncology recommended use of the MammaPrint test to identify women who need chemotherapy and those who do not.
Agendia N.V. (Amsterdam, the Netherlands) markets MammaPrint, a 70-gene signature chip, to assess the risk of breast cancer recurrence...